Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus

NCT03858634 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03858634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03858634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2019
Completion date
June 8, 2020
Enrollment
58 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic pruritus, chronic idiopathic urticaria, lichen planus, lichen simplex chronicus, plaque psoriasis